Company intelligence / Profile preview
Leads Biolabs
Nanjing, Chinaen.leadsbiolabs.com ↗
- Ownership
- Public · 09887
- Development stage
- Other
01
Overview
Multiple programs in clinical development including LBL-007 (LAG-3 antibody) with Phase Ib/II results published in Journal of Hematology & Oncology, LBL-034 (GPRC5D/CD3 bispecific antibody) received Orphan Drug Designation from FDA for multiple myeloma, and LBL-024 (PD-L1/4-1BB bispecific antibody) in development for neuroendocrine cancer
- Therapeutic areas
- OncologyImmunologyMetabolic Disorders
- Modalities
- Monoclonal antibodiesbispecific antibodiesT cell engagersantibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
Aditum Bio (formed Oblenio Bio to develop LBL-051)
04
Financials
- Market cap
- $909.9M
- Total revenue
- $29.6M
- Enterprise value
- $779.7M
Beyond the preview
Go deeper on Leads Biolabs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leads Biolabs.